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Introduction
Due to its clinical heterogeneity and unpredictable course
childhood systemic lupus erythematosus (JSLE) represents
one of the most challenging conditions in rheumatology.
We have audited our unit’s clinical practice in order to
determine not only characteristics of our patient cohort,
but also to identify potential for our clinical care
improvement.
Objectives
To evaluate clinical presentation, therapeutic approaches
and disease outcome in a cohort of children with JSLE
in a single central European centre.
Methods
Electronic records of patients attending the Unit over the
period from January 2005 (when hospital information
system was established) to April 2012 were reviewed.
Inclusion criteria were diagnosis of SLE according to the
modified ACR classification criteria in patients aged ≤18
years and active disease requiring daily steroid dose higher
than 5 mg. Data on clinical and laboratory findings and
treatment modalities from the entry and the last clinic
visits were analyzed.
Results
27 cases were identified, 26 Caucasians, 23 (85%)
females, with the mean age at the diagnosis 14,1 years
(± 3,3). In 22 cases JSLE diagnosis was made within the
analyzed time period, in 5 patients with earlier disease
onset older data were retrieved from the notes. Mothers
of 2 patients suffered with SLE as well. Patients were
followed for a mean period of 3,7 years (± 2,2). At the
diagnosis, 17 (63%) patients had skin involvement, 18
(67%) musculoskeletal manifestations and 4 (15%)
neurological involvement. Patients presented with cyto-
penia (n = 16; 59%), positive ANA (n = 25;93%) and
anti-dsDNA (n = 18;67%). In 10 patients (37%) renal
involvement was noted, in 4 patients at disease onset, in
2 cases during the first year of the disease and in 4
cases nephritis evolved after the mean of 3,8 years from
onset. Laboratory characteristics of antiphospholipid
syndrome were present in 17 (63%) patients, 5 had
thromboembolic complications and 3 had chorea. All
patients were treated with corticosteroids, most of them
in combination with hydroxychloroquine (93%),
azathioprine and methotrexate were administered to 11
(41%) and 7 (26%) patients respectively, 4 patients were
treated with cyclosporine, 6 with i.v. cyclophosphamide
and 1 with mycophenolate mofetil. At the time of data
analysis 13 patients were still followed by us, 4 of them
were in clinical remission on maintenance therapy and 9
had mild or moderate disease activity on combined
immunosuppression. Transition to rheumatology service
was completed in 14 patients at the mean age of 19
years, 10 of them had still active disease at the time of
transfer.
Conclusion
Number of patients followed at our Unit reflects low
incidence of SLE in our population (total 10 million)
and underlines importance of centralised care in order
to accumulate and maintain relevant disease manage-
ment expertise. Having analysed our records critically
we have noted paucity of important data including
patient-reported disease outcomes as well as systematic
disease assessments (SLEDAI, SLICC). Despite this we
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have been able to demonstrate distribution of organ
involvement and disease severity as reflected in treat-
ments used. Although none of the patients died during
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